Alnylam Pharmaceuticals ALNY Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's total cost of revenue?
- Alnylam Pharmaceuticals (ALNY) reported total cost of revenue of $207.52M in Q1 2026.
- How has Alnylam Pharmaceuticals's total cost of revenue changed year-over-year?
- Alnylam Pharmaceuticals's total cost of revenue increased by 195.7% year-over-year, from $70.18M to $207.52M.
- What is the long-term trend for Alnylam Pharmaceuticals's total cost of revenue?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's total cost of revenue has grown at a 55.8% compound annual growth rate (CAGR), from $115.01M to $677.17M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.